Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 13vPnC Vaccine in Elderly Adults Previously Vaccinated with 23vPS
NCT00500266Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of Prevnar 13 in pneumococcal infection, sponsored by Pfizer. Primary endpoints: Percentage of Participants With Pre-specified Local Reactions, Percentage of Participants With Pre-specified Systemic Events and 1 more. Started May 2008; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00500266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500266.